Introduction to RSV Drugs
The Food and Drug Administration (FDA) has initiated a safety review of two injectable drugs designed to protect babies and toddlers from Respiratory Syncytial Virus (RSV), a common virus that leads to hospitalization of thousands of American children annually. These long-acting drugs, developed by Merck and Sanofi, are not vaccines but rather laboratory-made versions of natural antibodies that aid the immune system in fighting off RSV.
Background on RSV and Its Impact
RSV is a seasonal virus that poses a significant threat to the very young and the elderly, although it is typically a cold-like nuisance for most healthy individuals. The virus can lead to severe illness, including bronchiolitis and pneumonia, necessitating hospitalization. Given the lack of vaccines approved for babies and young children, these injectable drugs have become a first-line treatment for protecting youngsters against RSV.
The FDA Safety Review
The FDA’s decision to open a safety review of these drugs comes at a time when health officials and advisers under Health Secretary Robert F. Kennedy Jr. are reevaluating recommendations on routine childhood vaccinations. A spokesman for Kennedy characterized the inquiry as a routine safety evaluation, emphasizing that the FDA will update product labeling if warranted by the evidence. Both Merck and Sanofi have stated that they have not identified any new safety signals with their medications, which were approved in recent years for infants and young children facing RSV.
The Drugs in Question
Merck’s Enflonsia and Sanofi’s Beyfortus are the two drugs under review. These medications are designed to provide protection against RSV by mimicking the natural antibodies that help the immune system combat the virus. Merck’s injection is approved for babies before or during their first RSV season, which typically lasts five months. Sanofi’s Beyfortus has been used to immunize over 6 million babies worldwide, with the company reporting no safety issues from clinical studies or post-marketing experience.
Recent Developments and Controversies
The announcement of the FDA’s safety review follows recent controversies surrounding vaccine recommendations. In 2023, Centers for Disease Control and Prevention (CDC) advisers recommended the antibody shots for infants born just before or during the RSV season, provided the birth mother wasn’t vaccinated late in pregnancy. Additionally, the panel recommended a dose for some 8- to 19-month-olds at higher risk of serious illness from RSV. Since taking over the Department of Health and Human Services, Kennedy replaced every member of the CDC committee, which also makes vaccine recommendations. This move has been followed by decisions such as urging an end to routine newborn vaccination against hepatitis B, triggering backlash from medical and scientific professional societies.
Conclusion
The FDA’s safety review of injectable RSV drugs for babies and toddlers marks a critical moment in the ongoing discussion about vaccine safety and efficacy. As the medical community and regulatory bodies continue to navigate the complexities of protecting vulnerable populations from RSV and other diseases, transparency and rigorous scientific review are paramount. The outcome of this review will have significant implications for public health policies and the protection of young children against RSV.
FAQs
- What is RSV, and why is it a concern?
RSV, or Respiratory Syncytial Virus, is a common virus that can cause severe illness in young children and the elderly, leading to hospitalization. - What are the drugs under FDA review?
The drugs in question are Merck’s Enflonsia and Sanofi’s Beyfortus, which are injectable medications designed to protect against RSV. - Why has the FDA initiated a safety review of these drugs?
The FDA has opened a safety review as part of its routine evaluation of drug safety, especially in light of recent discussions and changes in vaccine recommendations. - What are the implications of this review for public health?
The review’s outcome will significantly impact how RSV is managed in vulnerable populations, influencing public health policies and vaccine recommendations. - Are these drugs vaccines?
No, these drugs are not vaccines but rather laboratory-made antibodies that help the immune system fight off RSV.
By MATTHEW PERRONE
WASHINGTON (AP) — Food and Drug Administration officials have opened a safety review of two injectable drugs used to protect babies and toddlers from RSV, the respiratory virus that sends thousands of American children to the hospital each year.
The long-acting drugs from Merck and Sanofi are not vaccines, but the government review comes as health officials and advisers under Health Secretary Robert F. Kennedy Jr. roll back recommendations on routine childhood vaccinations.
A spokesman for Kennedy described the inquiry as a routine safety evaluation and said the FDA “will update product labeling if warranted by the totality of the evidence.”
The two drugmakers said in separate statements that they haven’t seen any new safety signals with their medications, which were approved in recent years for infants and young children facing RSV.
News of the review was first reported by Reuters.
The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA has approved vaccines for older patients and pregnant women but not babies or children, making the injections a first-line treatment for youngsters against the seasonal virus.
A spokesperson for Merck, maker of Enflonsia, said company representatives met with the FDA last week.
“We expect questions from the FDA, and we want them to ask,” the company said. “We believe deeply in the importance of transparency and we value the FDA’s rigorous review of our clinical data of all of our products.”
Merck’s injection is approved to protect babies before or during their first RSV season, which typically lasts five months.
A spokesperson for Sanofi said it regularly submits any potential safety concerns to the FDA for review, but hasn’t seen any new signals with its drug across more than 50 studies.
“At this time, no safety issue has been identified from clinical studies of (Beyfortus) or from post-marketing experience with more than 6 million babies immunized worldwide,” the company said in a statement.
An infection with RSV is a coldlike nuisance for most healthy people, but it can be life-threatening for the very young and the elderly.
In 2023, Centers for Disease Control and Prevention advisers recommended the antibody shots for infants born just before or during the RSV season — if the birth mother wasn’t vaccinated late in pregnancy. The panel also recommended a dose for some 8- to 19-month-olds at higher risk of a serious illness from RSV.
Since taking over the Department of Health and Human Services, Kennedy replaced every member of the CDC committee, which also makes vaccine recommendations.
Last week, the panel urged an end to routine newborn vaccination against hepatitis B, a virus that can cause liver failure or liver cancer. The decision triggered swift backlash from numerous medical and scientific professional societies.
Separately, officials at the FDA have been scrutinizing the safety of vaccines, particularly COVID-19 shots, and floated plans for a wholesale overhaul of the agency’s decades-old approach to approving and reviewing vaccines.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
